The consumption of food for pleasure is mainly associated with adverse health effects. This review was carried out to verify recent reports on the impact of chocolate and wine consumption on cardiovascular health, with a particular focus on atherosclerosis. On one side, these products have proven adverse effects on the cardiovascular system, but on the other hand, if consumed in optimal amounts, they have cardiovascular benefits. The submitted data suggest that the beneficial doses are 30–50 g and 130/250 mL for chocolate and wine, respectively, for women and men. The accumulated evidence indicates that the active ingredients in the products under consideration in this review are phenolic compounds, characterized by anti-inflammatory, antioxidant, and antiplatelet properties. However, there are also some reports of cardioprotective properties of other compounds such as esters, amines, biogenic amines, amino acids, fatty acids, mineral ingredients, and vitamins. Our narrative review has shown that in meta-analyses of intervention studies, consumption of chocolate and wine was positively associated with the beneficial outcomes associated with the cardiovascular system. In contrast, the assessment with the GRADE (Grading of Recommendations Assessment, Development and Evaluation) scale did not confirm this phenomenon. In addition, mechanisms of action of bioactive compounds present in chocolate and wine depend on some factors, such as age, sex, body weight, and the presence of additional medical conditions. Patients using cardiovascular drugs simultaneously with both products should be alert to the risk of pharmacologically relevant interactions during their use. Our narrative review leads to the conclusion that there is abundant evidence to prove the beneficial impact of consuming both products on cardiovascular health, however some evidence still remains controversial. Many authors of studies included in this review postulated that well-designed, longitudinal studies should be performed to determine the effects of these products and their components on atherosclerosis and other CVD (Cardiovascular Disease) disease.

Background: The introduction of modern sub-perception modalities has improved the efficacy of spinal cord stimulation (SCS) in refractory pain syndromes of the trunk and lower limbs. The objective of this study was to evaluate the effectiveness of low and high frequency SCS among patients with chronic pain. Material and methods: A randomised, semi-double-blind, placebo controlled, four period (4 × 2 weeks) crossover trial was conducted from August 2018 to January 2020. Eighteen patients with SCS due to failed back surgery syndrome and/or complex regional pain syndrome were randomised to four treatment arms without washout periods: (1) low frequency (40-60 Hz), (2) 1 kHz, (3) clustered tonic, and (4) sham SCS (i.e., placebo). The primary outcome was pain scores measured by visual analogue scale (VAS) preoperatively and during subsequent treatment arms. Results: Pain scores (VAS) reported during the preoperative period was M (SD) = 8.13 (0.99). There was a 50% reduction in pain reported in the low frequency tonic treatment group (M (SD) = 4.18 (1.76)), a 37% reduction in the 1 kHz treatment group (M (SD) = 5.17 (1.4)), a 34% reduction in the clustered tonic settings group (M (SD) = 5.27 (1.33)), and a 34% reduction in the sham stimulation group (M (SD) = 5.42 (1.22)). The reduction in pain from the preoperative period to the treatment period was significant in each treatment group (p < 0.001). Overall, these reductions were of comparable magnitude between treatments. However, the modality most preferred by patients was low frequency (55% or 10 patients). Conclusions: The pain-relieving effects of SCS reached significance and were comparable across all modes of stimulation including sham. Sub-perception stimulation was not superior to supra-perception. SCS was characterised by a high degree of placebo effect. No evidence of carryover effect was observed between subsequent treatments. Contemporary neuromodulation procedures should be tailored to the individual preferences of patients.

Introduction: Recent research are focused on natural compounds for preventing cardiovascular diseases, with emphasis on tyrosol and hydroxytyrosol in olive oil. Cardiovascular diseases are linked to risk factors, and adopting a Mediterranean diet rich in these compounds is recognized for reducing risks. Understanding these compounds' actions may inform new strategies for preventing and treating cardiovascular diseases. Aim: The aim of this paper is a systematic review of articles and research regarding the Role of tyrosol and hydroxytyrosol in Cardioprotection Review methods: An systematic review of scientific literature was conducted using the following keywords: Tyrosol, hydroxytyrosol, cardioprotection, cardiovascular diseases, olive oil cardioprotective role. Thirty-four articles published until 2023 were searched and analyzed. Abbreviated description of the state of knowledge: Tyrosol and hydroxytyrosol, prominent in olive oil, are studied for their potential cardioprotective properties. Linked to a Mediterranean diet, these compounds show promise in reducing cardiovascular disease risk. They counter oxidative stress, improve lipid profiles, and modulate inflammatory processes. Clinical studies suggest their positive impact, with tyrosol also explored as a potential anticoagulant. Ongoing research aims to uncover optimal doses and mechanisms, highlighting their significance in cardiovascular health. Conclusions: Tyrosol and hydroxytyrosol, found in olive oil, show promise in cardioprotection by combating oxidative stress, improving lipid profiles, and modulating inflammation. Clinical studies suggest their positive impact on cardiovascular health. Tyrosol has potential as a anticoagulant and exhibits antioxidant effects. These compounds present a compelling avenue for future therapeutic interventions, with emphasis on understanding mechanisms and optimizing supplementation.

The purpose of this paper is a systematic review of articles and research in the context of drugs used and suicide in elderly patients. Suicide in the elderly may be much more frequent than in the younger population. In addition to factors such as mental illness, dementia, deteriorating health, or problems with adapting to old age, the impact of chronic and reliever medications in this age group should also be considered. The greatest challenge of pharmacotherapy in the elderly is polypharmacy, drug interactions, different metabolism, pharmacokinetics and pharmacodynamics of the drugs used, as well as the side effects appearing in chronic therapy. In elderly patients, strong groups of drugs such as benzodiazepines and opioids are used extensively and sometimes too often. These drugs can cause addiction and overdose. Prescribing benzodiazepines alone carries a high risk of suicide. On the other hand, opioids often lead to addiction and abuse of these drugs, which may be associated with the development of respiratory depression. According to estimates by the Centers for Disease Control and Prevention (CDC), suicide accounts for approximately 7% of all opioid overdose deaths. Therapy should be carefully selected with regard to the use of other medications, drug interactions, and possible dependence and drug abuse by patients.The use of some classes of drugs in the elderly requires increased vigilance and control in the context of depression and episodes of suicide attempts. Drugs such as B blockers, digitalis glycosides, NSAIDs, opioids, ACEIs, calcium channel blockers, corticosteroids, diuretics, levodopa, and benzodiazepines can cause symptoms of depression. Older people are more susceptible to side effects of drugs, for example because of polypharmacy and the chronicity of treatment.

Aim: The aim of this article is to review the latest scientific research on the influence of intestinal microbiota on the development of diseases. In this article we will discuss the importance of the intestinal microbiota, the differences in the composition of the microbiota between healthy and sick people and the relationship between the intestinal microbiota and metabolic, inflammatory, cardiovascular and neurodegenerative diseases. Abbreviated description of the state of knowledge: The gut microbiota plays a key role in human health by influencing the development and progression of various diseases. Numerous studies have shown that an imbalance in gut microbiota, called dysbiosis, may be linked to a number of conditions. Intestinal microflora interacts with the immune system, modulates inflammation and influences metabolic pathways, which emphasizes its importance in the development of diseases. Conclusions: Intestinal microflora is crucial to health, regulating immune, metabolic and neurological functions. Dysbiosis, i.e. disturbance of the balance of intestinal microflora, is associated with diseases such as type 2 diabetes, obesity, inflammatory bowel diseases, allergies, autoimmune diseases and neuropsychiatric disorders. Healthy microflora, influenced by diet, pH and nutrients, are essential for metabolism, immune system regulation and neuronal communication. Recently, scientists have become interested in the possibility of using this knowledge in treatment. Appropriate dietary management, probiotic supplementation and fecal microflora transplantation show promising potential. Future research should focus on elucidating the specific mechanisms by which the gut microbiota influences disease processes and developing targeted therapies to exploit the therapeutic potential of the microbiota.

Introduction: Urinary incontinence is a prevalent health issue that profoundly impacts the quality of life for patients worldwide. Traditional treatments, including pharmacotherapy and surgical procedures, often fall short, leaving many individuals struggling with bladder control issues that restrict physical and social activities and cause significant psychological distress. Recent advancements in therapeutic methods—encompassing behavioral therapies, cutting-edge medical technologies, innovative pharmacotherapy, and advanced surgical techniques—offer promising alternatives. By exploring the effectiveness and advantages of these novel approaches, we can enhance treatment accessibility and elevate the quality of care for those affected by urinary incontinence, ultimately improving their daily functioning and overall well-being. Abbreviated description of the state of knowledge:Current research on innovative treatments for urinary incontinence indicates significant advancements in enhancing patients' quality of life. These cutting-edge methods encompass behavioral therapies like pelvic floor muscle training, state-of-the-art medical technologies such as nerve stimulation, new pharmacological treatments with high efficacy and minimal side effects, and advanced surgical interventions, including artificial sphincter implants and urinary tract modifications. Conclusions: Urinary incontinence is a prevalent health issue that significantly deteriorates the quality of life, particularly affecting half of women and one-third of men over the age of 80. As our society ages and the number of individuals affected by this condition rises, understanding and advancing treatment methods become increasingly crucial. Ongoing research aims to discover new and improved therapeutic approaches with minimal side effects, offering hope for enhanced patient outcomes and better management of urinary incontinence in the future.